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Abstract
Background: Acute kidney injury (AKI) is often observed in critically ill patients and is associated with high
morbidity and mortality. Non-recovery from AKI has a negative impact on the prognosis of affected patients and
early risk stratification seems key to improve clinical outcomes. We analyzed metabolites of a conserved key
inflammatory pathway (i.e. tryptophan degradation pathway) in serial urine samples of patients with AKI.
Methods: One hundred twelve ICU patients with AKI were included in a prospective observational analysis. After
exclusion criteria, 92 patients were eligible for analysis. Serial urine samples were collected and tryptophan levels
including key tryptophan metabolites were measured using tandem mass spectrometry.
Results: Sixty-seven patients recovered in the first 7 days of AKI (early recovery, ER) whereas n = 25 had late−/non-
recovery (LNR). Urinary concentrations of tryptophan, kynurenine, 3-OH anthranillic acid, serotonine, and kynurenine/
tryptophan were significantly lower in LNR patients. In contrast, creatinine normalized excretion of kynurenic acid (KynA)
was substantially increased in LNR patients (7.59 ± 6.81 vs. 3.19 ± 3.44 (ER) μmol/mmol, p < 0.005). High urinary KynA
excretion was associated with higher RIFLE class, longer AKI duration, increased need for RRT, and 30-day mortality.
Logistic regression revealed KynA as the single most important predictor of renal recovery on days 1 and 2 of AKI.
Conclusions: Increased urinary levels of kynurenic acid, a key inflammatory metabolite of the tryprophan degradation
pathway, are associated with adverse renal and clinical outcomes in critically ill patients with AKI. Urinary KynA may serve
as an early risk stratificator in respective patients with AKI.
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Background
AKI (acute kidney injury) is common in critically ill pa-
tients in intensive care units and is associated with high
morbidity and mortality [1, 2]. Development and validation
of an AKI definition resulted in a huge progress in regard
to the understanding of AKI in the last 12 years. Moreover,
renal outcome analysis after survival from AKI has become
an important field of scientific interest [3–6]. In addition,
AKI is associated with an increased risk for chronic kidney
disease [5] and non-recovery from AKI is associated with
decreased long-term survival, indicating the importance of
novel strategies designed to improve recovery from AKI
[6]. Prediction of recovery from AKI seems therefore
important to identify respective patients at increased risk.
Recent studies focussed on renal recovery in AKI patients
[7–10] and biomarkers with a special focus on inflamma-
tory markers were investigated (e.g. NGAL [7], cytokines
[8], inflammatory markers, hepatocyte growth factor, cysta-
tin C and creatinine [9]). Using proteomics, we recently
identified urinary insulin-like growth factor binding protein
7 (IGFBP-7) as a marker for prognosis in AKI [10].
Tryptophan (Trp) is an essential amino acid which
undergoes degradation via the immunoregulatory enzyme
indoleamine 2,3-dioxygenase (IDO) and, to a less extent,
tryptophan 2,3 dioxygenase (TDO). The degradation of
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tryptophan along the IDO-pathway is a key and highly
conserved inflammatory pathway that was previously
shown important in a number of clinical conditions asso-
ciated with acute and chronic inflammation, including
renal allograft rejection [11] and chronic kidney disease
(CKD) [12]. We previously demonstrated increased levels
of IDO activity in patients with CKD and found a stepwise
increase in Trp catabolite concentrations with advancing
CKD class [12]. In fact, enzymatic degradation of trypto-
phan was shown to occur in numerous diseases such as
stroke [13], severe infection [14, 15], hepatic dysfunction
[16], and cardiac arrest [17, 18], which underlines the
importance of the tryptophan degradation pathway as a
key inflammatory pathway.
The rate of tryptophan degradation expressed by the
ratio of substrate (tryptophan, trp) to metabolite (kynur-
enine, kyn) kyn/trp was reported to serve as an estimate
of IDO activity [11, 12]. Moreover, the urinary Kyn/Trp
ratio showed a strong dose-response relationship with
incident myocardial coronary events, acute myocardial
infarction, and mortality in a large cohort of stable pa-
tients undergoing coronary angiography [19] which may
furthermore point to a significant clinical relevance of
this inflammatory pathway.
The aim of the present study was to analyze urinary
tryptophan excretion and levels of tryptophan metabolites
in the urine of critically ill patients with AKI. We therefore
analyzed serial urine samples collected during the first
days of AKI. Urinary excretions were assessed in patients
with early recovery (ER) and late−/non-recovery (LNR)
from AKI using tandem mass spectrometry.
Methods
The study was performed as a sub-investigation of a pro-
spective proteomic AKI study [10]. Urine samples were
prospectively collected from AKI patients at the medical
ICU of the University Hospital Charité Campus Virchow-
Klinikum, Berlin, and at the surgical ICU of the “German
Heart Center Berlin” between 2010 and 2011. These pa-
tients corresponded to a “discovery group” which served
as source for the proteomic approach. Inclusion criteria
were: AKI (please note definition provided below) diag-
nosed in adults (age > 18 years) on the first day of AKI.
Exclusion criteria were follow-up period of less than
7 days, presence of macrohematuria, end-stage renal dis-
ease, and renal transplantation.
Study population and collection of urinary samples
One hundred twelve AKI patients were enrolled in the
study. Twenty patients were excluded due to death during
follow-up, lost to follow-up, or wrongful inclusion (i.e. pa-
tients whose baseline creatinine concentration later turned
out as increased and did thus not qualify for AKI according
to the given definition). A study flow chart is given in Fig. 1.
In total, 92 patients were eligible for analysis. Of these, 67
(73%) patients recovered during the first week after AKI
(early recovery, ER) and n = 25 (27%) did not (late−/non-re-
covery, LNR). Aliquots of spot urine samples (drawn from
respective catheters) were collected between 9 am and
11 am on the respective days of AKI, and were centrifuged,
aliquoted and stored at − 80° until analysis. All samples
were thawed only once prior to analysis.
Definition of AKI
AKI was defined according to the RIFLE classification
[20]. Only patients with a known baseline creatinine
concentration were considered. Baseline creatinine was
defined according to the method suggested by Pickering
with one modification [21]: in patients hospitalized
longer than 10 days on ICU, we deliberately defined
baseline creatinine concentration as the lowest creatinine
concentration during the ICU stay before development of
AKI. GFR was estimated according to the Modification of
Diet in Renal Disease (MDRD) equation. Recovery was
defined as not classifying for any RIFLE class during
the follow-up time of 7 days. Creatinine concentra-
tions were determined daily.
Assessment of tryptophan degradation products
Tryptophan metabolties were measured as previously
reported [12, 22, 23]. In summary, Trp and respective
metabolites were measured using tandem mass spec-
trometry in line with the procedure proposed by Zhu et
al. [24]. For determination of creatinine levels, the
method of Husková was modified to fit to the existing
method [25]. Commercially available Trp, Kyn, KynA,
quinolinic acid (QuinA), 5-hydroxy tryptophan (OH-
Trp), 3-hydroxy anthranilic acid (3-OH-AA), seroto-
nine, phenylalanine (all Sigma-Aldrich, St. Louis, USA)
and creatinine (Cr) from Merck (Darmstadt, Germany),
Fig. 1 Study design. Urine was collected on the first 3 days in 112
acute kidney injury (AKI) patients on the intensive care unit. Urinary
concentrations of tryptophan and respective metabolites were
assessed on the first 3 days of AKI. After 1 week, recovery status was
assessed. Results are compared between patients with early recovery
(ER) and late−/non-recovery (LNR)
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deuterium labelled compounds Kyn-d6, KynA-d5, Phe-d5,
Trp-d5 (all Cambridge Isotope Laboratories, Andover,
MA, USA), Cr-d3. (C/D/N Isotopes Inc., Pointe-Claire,
QC, Canada), water (Optima MS grade, Fisher Scientific,
Waltham, USA) and acetonitrile (Optima grade, Fisher
Scientific, Waltham, USA) were used. One hundred mi-
croliters of urine were added to a deuterated internal
standard (IS) mixture (50 μl) of equal volumes of Kyn-d6,
Kyn A-d5, Phe-d5, Trp-d5 and Cr-d3. After shaking of the
solution for 2 min, 500 μL acetonitrile was added and left
over night at − 20 °C to precipitate the protein. Samples
were centrifuged (20,000 g, 10 min), and the supernatant
was dried under vacuum centrifugation (Savant SpeedVac
Plus SC210A and Savant Refrigerated Vapor Trap RVT
4104). Dried samples were reconstituted with 100 μL
H2O/acetonitrile (95%/5%). A Waters Acquity UPLC-
TQD system (Milford, MA, USA) was equipped with an
electrospray ion source using MRM detection in a positive
ion mode. The following transitions of mass-to-charge
ratios (m/z) of 205/188 for Trp, 210/193 for Trp-d5, 209/
192 for Kyn, 215/198 for Kyn-d6, 168/150 for Quin, 190/
144 for Kyna, 195/149 for Kyna-d5, 154/136 for 3HAA,
177/160 for Ser, 221/204 for OH-Trp, 166/120 for Phe,
171/125 for Phe-d5, 114/86 for Cr, and 117/89 for Cr-d3
were detected using argon as a collision gas. For separ-
ation of analytes, an Acquity UPLC BEH C18 column
(1.7 μm, 100 mm) was used. A gradient of water/aceto-
nitrile was utilized starting at a ratio of 97/3 and ramping
up to a ratio of 70/30 in 5 min using a flow rate of
0.35 mL/min. Calibration curves were performed for
quantification and referring the analytes to appropriate
deuterated standards. Calibration curves were fitted by
linear least-square regression. Serum (ClinChek- Control,
Recipe, Germany) with known Phe and Trp concentra-
tions was used as quality control to ensure the accuracy
and precision of both the sample preparation and the
measurements produced by the ultra performance liquid
chromatography (UPLC)-MS/MS. Plasma creatinine con-
centrations were measured using a Roche-Cobas clinical
chemistry autoanalyzer (Roche Diagnostics, Switzerland).
In one NR patient estimated urinary creatinine concentra-
tions were unrealistically low and negative on day 2. Urine
samples of this individual patient were thus excluded from
statistical analyses.
Statistical analysis
Data are given as mean ± standard deviations. Nonpara-
metric tests (Mann-Whitney U test) were done whenever
appropriate. Correlation analysis were performed using
Spearman’s rank correlation coefficient. Sensitivity, spe-
cificity, 95% CI, and AUC was calculated with Graph-
Pad Prism v.7.0a (GraphPad Software, San Diego, CA).
Univariate and multivariate logistic analyses, receiver
operating characteristics and mixed effects models were
performed using SAS 9.4 on a X64 VSPRO platform (SAS
Institute, Cary, NC) using the procedures LOGISTIC,
GLIMMIX and NLMIXED.
Results
Samples from 92 patients with AKI were analysed (Fig. 1).
Baseline characteristics of 67 patients with and 25 patients
without early recovery are given (Table 1). Patients in both
Table 1 Baseline characteristics
Early
recovery
Late/Non-
Recovery
p
Number 67 25
Age, years (mean ± SD) 68 ± 14 65 ± 15 NS
Female gender, n (%) 19 (28) 11 (44) NS
Hypertension, n (%) 43 (64) 15 (60) NS
Diabetes, n (%) 21 (31) 6 (24) NS
Baseline creatinine level,
mg/dl (mean ± SD)
0.97 ± 0.38 0.98 ± 0.41 NS
Chronic kidney diseasea,
n (%)
19 (28) 5 (20) NS
ICU admission due to
Cardiovascular disease, n (%) 18 (27) 5 (20) NS
Infection, n (%) 10 (15) 6 (24) NS
Neurological disease 5 (7) 2 (8) NS
Liver failure 1 (1) 3 (12) NS
Kidney failure 2 (3) 1 (4) NS
Surgery 31 (46) 8 (32) NS
Time from ICU admission
to day 1, days (median (IQR))
1 (IQR1-3) 1 (IQR 1-12) NS
Patients with SIRS on day 1, n (%) 42 (63) 19 (76) NS
Patient with SIRS and infection
on day 1, n (%)
6 (9) 6 (24) NS
APACHE 2 score on admission,
(mean ± SD)
27 ± 7 32 ± 7 < 0.005
SOFA scoreb on day 1,
(mean ± SD)
9 ± 4 12 ± 4 < 0.005
Patients under vasoactive
drugs, n (%)
42 (63) 18 (72) NS
Invasive ventilation, n (%) 47 (70) 20 (80) NS
Creatinine on day 1, mg/dl
(mean ± SD)
0.97 ± 0.38 0.98 ± 0.41 NS
Oliguriac on day 1, n (%) 7 (10) 3 (12) NS
Hemoglobin on day 1, g/dl
(mean ± SD)
108 ± 16 99 ± 20 < 0.05
Thrombocyte count on
day 1, x 109/l (mean ± SD)
188 ± 98 130 ± 88 < 0.05
C reactive protein on day 1,
mg/l (mean ± SD)
14 ± 10 12 ± 11 NS
aChronic kidney disease defined as eGFR< 60 ml/min (MDRD formula), bSOFA score
without renal SOFA score, cOliguria defined as urinary output < 500 ml per day
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groups were comparable regarding comorbidities, and
distribution of age and gender. Baseline disease severity as
assessed using the APACHE II scoring system [26] and
SOFA score on the first day of AKI was higher in LNR
patients. Furthermore, haemoglobin concentrations and
thrombocyte counts on day 1 of AKI were lower in LNR
patients. Of note, creatinine concentrations on the first
day of AKI did not differ between the two groups
(p = 0.2). As expected, renal function during the
follow-up time of 7 days was reduced in LNR patients
(Table 2) and respective patients required RRT therapy
more often, received more transfusions, had a longer
hospital and ICU-stay, and had a higher 30-day
mortality.
Urinary excretion of tryptophan metabolites
On day 1 of AKI, urinary creatinine normalized concentra-
tions of Trp, Kyn, 3-OH-Anthranilic acid (3-OH-AA),
serotonine, phenylalanine, OH-Trp and Kyn/Trp were not
different between the two groups (Table 3). Creatinine nor-
malized urinary concentrations of KynA (ER: 3.19 ± 3.44
μmol/mmol vs. LNR: 7.59 ± 6.81 μmol/mmol creatinine,
p < 0.005) and the ratio of KynA to Trp (ER: 1.37 ± 2.86
μmol/mmol vs. LNR: 2.30 ± 2.73 μmol/mmol, p = 0.01)
were higher in LNR patients (Table 3, Fig. 2). Increased
concentrations of KynA in LNR patients were consistently
observed on days 2 and 3 of AKI (Fig. 2). The same applied
to the ratio of KynA/Trp. On day 3, creatinine normalized
urinary concentrations of Trp, Kyn, 3OH-AA and seroto-
nine in LNR patients were lower as compared with ER
patients and so was the ratio of Kyn/Trp.
Prognostic performance of tryptophan metabolites
Logistic regression analysis revealed KynA as the single
most important predictor of renal recovery on days one
and two of AKI (score Х2 = 12.7, p < 0.0004, and Х2 =
20.6, p < 0.0001, respectively). On AKI day 3, the single
most important predictor of renal recovery was serum
creatinine (Х2 = 17.3, p < 0.0001). Using multivariate
logistic analysis with stepwise selection from SOFA score
at admission, serum creatinine, eGFR, diuresis, KynA and
the ratio of KynA to Trp revealed the following best models
to predict outcome: day 1: KynA (Х2 = 12.7, p < 0.0004)
and SOFA score at admission (Х2 = 6.1, p < 0.0134), day 2:
KynA (Х2 = 20.6, p < 0.0001) and serum creatinine
(Х2 = 8,4, p < 0.0039) and day 3: serum creatinine
(Х2 = 17.3, p < 0.0001) and the ratio of KynA to Trp
(Х2 = 7.6, p < 0.0059). Combining the data of all 3 days
into one logistic mixed effects model revealed no sig-
nificant improvement when the ratio of KynA to Trp as
compared to KynA was modelled together with the
SOFA score at admission and serum creatinine levels
(Akaike information criterion AIC 103.6 vs. 102.5).
Potential predictors of early recovery on day 1 of AKI
are given in Table 4.
ROC analyses of KynA revealed an AUC for predicting
renal recovery of 0.72 for KynA (95%- CI: 0.59-0.85, p <
0.003) on day 1, 0.80 (95%-CI 0.69-0.93, p < 0.003) on
day 2 and 0.78 (95%-CI 0.66-0.90, p < 0.023) on day 3
(Fig. 3a–c). When SOFA scores at admission and serum
creatinine concentrations were included into the model,
the prognostic power improved to an AUC of 0.93 (95%-
CI 0.87-1.00, p < 0.011) on day 3. AUC of KynA/Trp to
predict recovery revealed 0.69 (95%-CI 0.56-0.79, NS) on
day 1, 0.88 (95% CI 0.80-0.96, p < 0.002) on day 2 and
0.90 (95% CI 0.80-1.00, p < 0.001) on day 3, respectively
(Fig. 3d–f ). When SOFA score and serum creatinine
concentration were included into the model, AUC fur-
ther improved and revealed 0.95 (95%-CI 0.90-1.00)
on day 3. AUCs on day 1 for Trp and all other metab-
olites did not reach statistical significance (data not
shown).
Correlation analysis of Trp metabolites
We observed a negative correlation of urinary KynA
excretion on day 1 with eGFR (r = − 0.24, p < 0.05) and
for KynA/Trp with eGFR (r = − 0.51, p < 0.0001). KynA
and the ratio of KynA/Trp on day one correlated with
AKI duration (r = 0.4, p < 0.0001 and r = 0.39, p <
0.0005, respectively), the need for renal replacement
therapy (r = 0.39, p < 0.0005 and 0.30, p < 0.005 respect-
ively), and non-recovery (r = 0,35, p < 0.001 and r = 0.27,
p < 0.01 respectively). KynA was furthermore found to
correlate with 30- and 90-day mortality (r = 0.28, p < 0.001
and r = 0.25, p < 0.005, respectively).
Table 2 Clinical outcomes of study patients
Early
Recovery
Late/Non-
Recovery
p-value
Number 67 25
Maximum creatinine level,
mg/dl (mean ± SD)
2.0 ± 0.9 3.6 ± 2.0 < 0.0001
Minimal eGFR, ml/min (mean ± SD) 45 ± 25 21 ± 9 < 0.0001
RIFLE class, R/I/F 42/18/7 0/6/19 < 0.0001
Duration of AKI, days (mean ± SD) 3.0 ± 1.8 21.5 ± 19.8 < 0.0001
Patients on RRT, n (%) 2 (3) 15 (63) < 0.0001
Patients with RBC transfusions, n (%) 30 (45) 19 (76) 0.01
Red blood cell transfusions, n
(mean ± SD)
1.4 ± 2.3 3.7 ± 4.1 < 0.001
Length of hospital stay, days
(mean ± SD)
34 ± 33 50 ± 31 < 0.005
Length of ICU stay, days (mean ± SD) 18 ± 20 31 ± 26 < 0.01
28-day mortality, n (%) 13 (20) 11 (46) < 0.05
90-day mortality, n (%) 25 (34) 15 (63) NS
AKI acute kidney injury, eGFR estimated glomerular filtration rate, ICU intensive
care unit, RBC red blood cellm, R Risk, I Injury, F Failure, RRT renal
replacement therapy
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Discussion
After analysis of serial urine samples from 92 AKI patients,
we found that urinary concentrations of KynA and the ratio
of KynA/Trp predict renal recovery on day 1 of AKI. Prog-
nostic performance furthermore improved when key clin-
ical characteristics such as SOFA score and serum
creatinine concentrations were included into the analysis.
Logistic regression analysis consistently revealed KynA as
the single most important predictor of renal recovery on
days 1 and 2 of AKI. High urinary KynA excretion was as-
sociated with higher RIFLE class, longer AKI duration, in-
creased need for RRT, renal non-recovery, and 30-day
mortality.
Patients without recovery from AKI had advanced renal
dysfunction and higher need for renal replacement ther-
apy, received an increased amount of transfusions, and
had both longer ICU- and hospital stay and increased
mortality. This finding is in line with previous data dem-
onstrating that non-recovery from AKI is associated with
decreased short-term and long-term outcomes [6, 27, 28].
Until now, there was no clear definition of recovery from
AKI and several autors suggested that a standardized def-
inition of renal recovery might improve our understanding
of factors associated with recovery [29, 30]. Very recently,
Table 3 Urinary concentrations of Tryptophan and respective metabolites
DAY 1 DAY 2 DAY 3
ER LNR p ER LNR p ER LNR p
Trp/cr umol/mmol 5.51 ± 4.95 6.10 ± 6.75 NS 9.50 ± 14.91 7.28 ± 7.84 NS 12.08 ± 10.49 6.0 ± 5.6 < 0.005
Kyn/cr umol/mmol 2.90 ± 4.87 2.94 ± 7.65 NS 3.88 ± 5.69 4.30 ± 8.80 NS 5.60 ± 8.17 2.2 ± 4.8 < 0.0001
KynA/cr umol/mmol 3.19 ± 3.44 7.59 ± 6.81 < 0.005 1.87 ± 1.10 9.17 ± 9.67 < 0.0001 2.00 ± 1.28 6.51 ± 9.49 < 0.001
3 OH AA/cr umol/mmol 1.36 ± 2.86 1.04 ± 1.82 NS 1.14 ± 1.62 0.72 ± 1.04 NS 2.02 ± 3.11 0.75 ± 0.99 < 0.05
Serotonine/cr umol/mmol 0.045 ± 0.075 0.053 ± 0.11 NS 0.038 ± 0.026 0.036 ± 0.041 NS 0.045 ± 0.035 0.027 ± 0.037 < 0.005
Phenylalanine/cr umol/mmol 5.50 ± 5.02 9.41 ± 12.84 NS 7.56 ± 11.80 9.77 ± 12.03 NS 8.49 ± 7.55 6.73 ± 6.81 NS
OH-Trp/cr umol/mmol 0.12 ± 0.18 0.23 ± 0.72 NS 0.11 ± 0.077 0.13 ± 0.106 NS 0.11 ± 0.068 0.11 ± 0.078 NS
KynA/Trp 1.37 ± 2.86 2.30 ± 2.73 < 0.01 0.47 ± 0.66 1.8 ± 1.8 < 0.0001 0.26 ± 0.20 1.33 ± 1.25 < 0.0001
Kyn/Trp 0.66 ± 1.24 0.34 ± 0.33 NS 0.64 ± 1.08 0.58 ± 0.93 NS 0.73 ± 1.58 0.30 ± 0.41 < 0.05
3OH AA 3-hydroxy anthranilic acid, cr creatinine, d day, ER early recovery, Kyn kynurenine, KynA kynurenic acid, LNR late−/non-recovery, OH-Trp 5-hydroxy tryptophan,
Trp tryptophan. Urinary concentrations of Trp and respective metabolites were normalized to urinary creatinine concentrations (except KynA/Trp ratio). Results are given
as mean ± standard deviations for the first 3 days of AKI (d1, d2, and d3)
Fig. 2 Urinary concentrations of kynurenic acid and kynurenic acid/
tryptophan ratio in AKI patients with/without early recovery. Results
are given on a linear scale and displayed as boxplot summaries. The
middle line in the box represents the mean, and the whiskers
represent the standard error of the mean. Urinary concentrations of
creatinine normalized kynurenic acid (KynA) were increased in
patients with late−/non-recovery (LNR) when compared to patients
with early recovery (ER) (*p ≤ 0.005, **p < 0.001 and ***p < 0.0001).
The urinary ratio of KynA/tryptophan was higher in LNR patients
compared to ER patients. (*p = 0.01, *** < 0.0001). Corresponding
serum creatinine concentrations in mg/dl are given below the graph
Table 4 Potential early predictors of renal recovery
ROC AUC CI 95% Wald χ2 P<
KynA 0.72 0.59-0.85 8.88 0.003
SOFA score 0.70 0.67-0.83 6.75 0.01
Delta diuresis
(day 1 – baseline), ml/h
0.68 0.55-0.81 3.84 0.05
Diuresis, ml/h 0.63 0.51-0.76 3.58 0.06
Delta serum creatinine
(day 1 – baseline)
0.61 0.47-0.74 2.14 0.14
Serum creatinine, mg/dL 0.59 0.46-0.72 1.38 0.24
All data based on the initial values collected on day one
KynA kynurenic acid, SOFA sepsis-related organ failure assessment score
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Fig. 3 Multivariate logistic regression model of renal recovery in AKI patients. ROC analyses for the prediction of renal recovery by urinary KynA
(a-c) and the ratio of urinary KynurA/cr to tryptophan/cr (d-f), respectively; alone (full line) and in combination with the clinical parameters
(SOFA score at admission and serum creatinine levels, dashed line) at days 1 (a, d), 2 (b, e) and 3 (c, f) of AKI
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the ADQI group proposed new definitions to define the
course of disease after AKI [31]. In this consensus report,
the group proposed new definitions reflecting the concept
of a continuum of ongoing kidney injury. The group pro-
posed AKI as a kidney injury lasting for 7 days, whereas
acute kidney disease (AKD) was proposed as an acute
renal damage for a duration between 7 and 90 days after
exposure to an AKI initiating event. CKD was defined as
persistent kidney disease 3 months after AKI. Even though
we designed our study long before, hazard definitions may
be regarded similar to the recent ADQI group consensus
definitions. If we would apply the definition suggested
by the ADQI group to our patients, we would com-
pare AKI (early recovery) versus AKD (late/non-re-
covery) patients. Our data therefore demonstrate that
patients with AKD have worse renal and non-renal
outcome and that these patients can be recognized as
early as day 1 of renal damage when analyzing trypto-
phan metabolites.
Reduced urinary excretion of Trp and most metabolites
as well as high urinary concentrations of KynA were asso-
ciated with poor clinical outcome. This seems in line with
our previous data demonstrating a stepwise increase of
plasma concentrations of Kyn, KynA, Serotonine and
increased IDO activity in patients with progressive CKD
while Trp plasma concentrations remain stable [12]. In
line with our previous results, other groups analyzed Trp
and respective metabolites in a rat model of CKD [32].
Plasma concentrations of Trp decreased slightly in severe
CKD, whereas plasma concentrations increased slightly
for Kynurenine and strongly for KynA (increase from 49
to 395 nM). Increased concentrations of KynA in the
serum of uremic patients was reported more than 30 years
ago [33] and the EUTox proposed KynA as an uremic
toxin [34]. Furthermore, the ratio of plasma KynA/Trp
was shown to be a sensitive marker for renal function in
hypertensive patients with CKD [35]. Of interest, using
liquid chromatography/mass spectrometry-based metab-
olite profiling, several markers including Kyn and KynA
were identified in patients from the Framingham study de-
veloping CKD at a later stage [36]. In a subgroup of these
patients, arterial and renal vein sampling was performed
and V/A ratios were calculated (0.84 for creatinine, 0.59
for KynA and 0.7 for Kyn). This may suggest net uptake
by the kidney via filtration, secretion, and/−or renal me-
tabolism/catabolism. The same group further analyzed
urinary excretion of these metabolites and showed frac-
tional excretion of KynA of 180% suggesting tubular KynA
excretion possibly via the human organic anion trans-
porter OAT1 and/or OAT3 [37]. In our study, urinary
excretion of KynA was negatively correlated with renal
function. However, although the current observational
study is unable to elucidate the underlying pathome-
chanisms involved in excretion of KynA, one might
speculate that increase activation of inflammatory path-
ways resulting increased production of KynA in AKI,
increased glomerular filtration, and increased release of
KnyA from apoptotic/necrotic sells may explain the
effects observed here.
Previously, urinary concentrations of Trp and its metab-
olites were not extensively studied. Urinary concentrations
of KynA were reported to range between 4 and 13 umol/l
in patients with normal renal function [38, 39]. Import-
antly, urinary concentrations of KynA in our AKI patients
were substantially higher. Assuming a daily creatinine
excretion of 10 mmol/day in our patients, daily excretion
of KynA would be around 32-76 umol. Except for KynA,
the urinary excretion of Trp and its metabolites decreased
with declined renal function. This might partialy explain
at least the superiority of the ratio of KynA to Trp over
KynA excretion with ongoing renal failure, i.e. on days 2
and 3 of AKI. There are concerns about whether urinary
AKI biomarkers should be normalized to urine creatinine
[40, 41]. The underlying assumption that creatinine excre-
tion is stable is flawed since there are dynamic changes in
urine creatinine excretion during AKI. However, in several
clinical studies, normalization of urinary biomarkers to
urinary creatinine concentration improved AKI prediction
[42]. We observed sligthly better performance of creatin-
ine normalized KynA to predict recovery when compared
to absolute concentrations (data not shown).
Our study has several limitations. First, patients
were analyzed in a single center and samples were
analyzed in a retrospective fashion despite prospective
collection of samples [10]. Second, urine aliquots ana-
lyzed in the present study were stored for a longer
period of time at − 80°. As this condition is identical
for all aliquots, only a systematic error might apply.
Third, although preferable, we are unable to provide
data of disease-matched control patients as they were
not available for the current analysis. Fourth, even though
we did not observe differences in the distribution of car-
diovascular or inflammatory disease between the groups,
we cannot rule out a potential bias introduced by such co-
morbidities. Fifth, nutritional intake of tryptophan and/or
tryptophan metabolites was not specifically investigated in
this study. Although short-term intake might be of minor
importance during the first days of critically illness, we are
unable to rule out an effect of nutritional intake on our
findings. Moreover, we observed associations rather than
underlying mechanisms in this analysis as elucidating
underlying pathomechanisms was beyond the scope of the
current analysis. Last, we excluded 20 patients from ana-
lysis of which 10 died in the follow-up of time of 7 days.
The reason for exclusion of these 10 patients was the
impossibility to assess renal recovery due to preceed-
ing death. Moreover, patients without known baseline
creatinine were excluded, which may have theoretically
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biased our observational data. Although the general
approach seems justifiable in a study on biomarkers to
predict renal recovery, patients with poorest prognosis
remain unstudied.
Conclusions
In conclusion, we observed that increased urinary excre-
tion of kynurenic acid measured on day 1 of AKI pre-
dicts renal non-recovery. High urinary kynurenic acid
concentrations correlated with higher RIFLE class, lon-
ger AKI duration, increased need for RRT, increased
rates of renal non-recovery, and increased mortality.
Assessment of urinary KynA might therefore serve as a
potential early risk stratificator in critically ill patients
with AKI. Our data may add to a better risk stratification
of affected patients in the future.
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